Filtered By:
Condition: Back Pain
Vaccination: Shingles (Herpes Zoster) Vaccine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Fight Aging! Newsletter, June 5th 2023
In conclusion, higher BMR might reduce lifespan. The underlying pathways linking to major causes of death and relevant interventions warrant further investigation. Betting Against Progress Turns Out Poorly, But Can Work in the Short Term in a Slow Field https://www.fightaging.org/archives/2023/06/betting-against-progress-turns-out-poorly-but-can-work-in-the-short-term-in-a-slow-field/ Setting oneself up as a spokesperson for "we will not achieve this goal", as the fellow noted here is choosing to do, is a bet against technological progress. A glance at any few decade period in the past two hundred year...
Source: Fight Aging! - June 4, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Herpes Zoster Following COVID-19 Vaccine Booster
CONCLUSIONS COVID-19 vaccination remains an important measure to prevent transmission of infection and to reduce the mortality and morbidity caused by it. However, healthcare practitioners should be aware of the possible association between COVID-19 vaccination and herpes zoster. Appropriate explanation and safety advice on the possible adverse events following COVID-19 vaccination, including herpes zoster infection, should be given to patients. This will facilitate early recognition and treatment of this condition.PMID:36650730 | DOI:10.12659/AJCR.938667
Source: Herpes - January 18, 2023 Category: Infectious Diseases Authors: Muhammad Shah Shahrudin Mohamed-Syarif Mohamed-Yassin Nik Munirah Nik Mohd Nasir Source Type: research

Zoster sine herpete
A previous patient came in with a new problem of severe right neck pain that wrapped around to the shoulder, about in a C4 distribution. Nothing on her C spine MRI to explain it, and her skin was hypersensitive to touch. Denied history of rash in the area but did have shingles several years ago on her face. Topicals weren’t helping and she got side effects with oral antineuropathics. She hadn’t had her shingles vaccine, so I told her to go ahead and get it, and that maybe it would help... Read more
Source: Student Doctor Network - December 5, 2022 Category: Universities & Medical Training Authors: callmeanesthesia Tags: Pain Medicine Source Type: forums

EE396 Public Health Impact and Cost-Effectiveness of Herpes Zoster Vaccination for Older Adults in the Netherlands
Varicella-zoster virus (VZV) causes chickenpox in children, and subsequently establishes a latent infection in dorsal root ganglia in the spinal cord. Decades later, it may reactivate, causing herpes zoster (HZ), a painful dermatomal skin rash ( “shingles”), in adults and especially in older individuals. Reactivation of latent VZV is mostly due to immunosenescence, i.e., an age-related functional decline of the immune system. A potential complication linked to HZ is postherpetic neuralgia (PHN), characterised by neuropathic pain which c an last for months or years.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: S Van der Pol, N Giannelos, S Joost, JC Wilschut, MJ Postma, C Boersma Source Type: research

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

What It Really Feels Like to Have Monkeypox
Since the global monkeypox outbreak began in May 2022, more than 22,000 cases have been confirmed in countries around the world. More than 5,000 of those cases have been recorded in the U.S., with many clustered in hotspots including New York and California. The virus, which often results in a blister-like rash and spreads through close contact, has so far predominantly affected men who have sex with men. Even as cases tick up and monkeypox gains public attention, however, it can still be difficult to find information about testing, treatment, and vaccines. Many people who fear they are at risk or infected are left to seek...
Source: TIME: Health - August 1, 2022 Category: Consumer Health News Authors: Jamie Ducharme, Angela Haupt and Jeffrey Kluger Tags: Uncategorized healthscienceclimate monkeypox Source Type: news

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

FDA Advisers Back a New COVID-19 Vaccine, Made By Novavax
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot. Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that’s made with a more conventional technology than today’s U.S. options. Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company. FDA’s vaccine chief Dr. Peter Marks said another choice in the U....
Source: TIME: Health - June 7, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 wire Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Serial Thoracic Transforaminal Epidural Steroid Injections for Post-herpetic Neuralgia: A Case Report
Cureus. 2022 Feb 1;14(2):e21808. doi: 10.7759/cureus.21808. eCollection 2022 Feb.ABSTRACTThe chronic neuropathic pain of post-herpetic neuralgia (PHN) often persists for months or years after the acute herpes zoster (shingles) episode, may be severe and intractable, and can severely impact the overall quality of life. Antivirals, analgesics, and nerve blocks can effectively shorten the course of shingles and may help to prevent PHN. Although vaccination effectively prevents shingles and PHN, current therapies may be ineffective, and pain management can be challenging when PHN occurs. A 78-year-old female with severe PHN pa...
Source: Herpes - March 7, 2022 Category: Infectious Diseases Authors: Bao N Dinh HuyKien Le John Dinh Joseph Mouhanna Marcos A Sanchez-Gonzalez Source Type: research

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect?
Clin Exp Vaccine Res. 2021 May;10(2):198-201. doi: 10.7774/cevr.2021.10.2.198. Epub 2021 May 31.ABSTRACTCoronavirus disease 2019 (COVID-19) exhibit mild to moderate symptoms, whereas 15% of COVID-19 cases progress to pneumonia, some associated cutaneous findings are also reported as maculopapular eruptions, morbilliform rashes, urticaria, chickenpox-like lesions, and livedo reticularis. The inactivated COVID-19 vaccines are authorized for use in some countries including Turkey. Here, we report an unusual case of varicella-zoster virus (VZV) reactivation in a 68-year-old male patient who was vaccinated against COVID-19. The...
Source: Cell Research - July 5, 2021 Category: Cytology Authors: Saliha Bu şra Aksu G üzin Zeren Öztürk Source Type: research